# Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)

> **NCT03234114** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 3746 (estimated)

## Conditions studied

- Acute Coronary Syndrome (ACS)
- Non-valvular Atrial Fibrillation (NVAF)

## Interventions

- **DRUG:** Triple antithrombotic therapy
- **DRUG:** Dual antithrombotc therapy-1
- **DRUG:** Dual antithrombotc therapy-2

## Key facts

- **NCT ID:** NCT03234114
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-02-03
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 3746 (ESTIMATED)
- **Last updated:** 2023-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03234114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03234114, "Optimal Antithrombotic Therapy for ACS Patients Concomitant With AF and Implanted With New-generation DES (OPTIMA-3, 4)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03234114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*